Literature DB >> 33067265

RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.

Srinivasa P Kolapalli1, Rinku Sahu1, Nishant R Chauhan1, Kautilya K Jena1, Subhash Mehto1, Saroj K Das2, Ashish Jain3, Manaswini Rout4, Rupesh Dash5, Rajeeb K Swain4, David Y Lee6, Tor Erik Rusten3, Santosh Chauhan7, Swati Chauhan8.   

Abstract

DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G1 arrest and defect in cell growth. Mechanistically, DZIP3 utilized its two different domains to interact and stabilize Cyclin D1 both at mRNA and protein levels. Using an RNA-binding lysine-rich region, DZIP3 interacted with the AU-rich region in 3' untranslated region of Cyclin D1 mRNA and stabilized it. Using a RING E3-ligase domain, DZIP3 interacted and increased K63-linked ubiquitination of Cyclin D1 protein to stabilize it. Remarkably, DZIP3 interacted with, ubiquitinated, and stabilized Cyclin D1 predominantly in the G1 phase of the cell cycle, where it is needed for cell-cycle progression. In agreement with this, a strong positive correlation of mRNA expression between DZIP3 and Cyclin D1 in different cancer types was observed. Additionally, DZIP3 regulated several cell cycle proteins by modulating the Cyclin D1-E2F axes. Taken together, this study demonstrates for the first time that DZIP3 uses a unique two-pronged mechanism in its stabilization of Cyclin D1 to drive cell-cycle and cancer progression. SIGNIFICANCE: These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/2/315/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33067265      PMCID: PMC7116596          DOI: 10.1158/0008-5472.CAN-20-1871

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  64 in total

Review 1.  E2F target genes: unraveling the biology.

Authors:  Adrian P Bracken; Marco Ciro; Andrea Cocito; Kristian Helin
Journal:  Trends Biochem Sci       Date:  2004-08       Impact factor: 13.807

Review 2.  The anaphase-promoting complex: a key factor in the regulation of cell cycle.

Authors:  Anna Castro; Cyril Bernis; Suzanne Vigneron; Jean-Claude Labbé; Thierry Lorca
Journal:  Oncogene       Date:  2005-01-13       Impact factor: 9.867

3.  Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E degradation.

Authors:  Leigh Ann Higa; Xiaoming Yang; Jianyu Zheng; Damon Banks; Min Wu; Papia Ghosh; Hong Sun; Hui Zhang
Journal:  Cell Cycle       Date:  2006-01-21       Impact factor: 4.534

4.  ATRX contributes to epigenetic asymmetry and silencing of major satellite transcripts in the maternal genome of the mouse embryo.

Authors:  Rabindranath De La Fuente; Claudia Baumann; Maria M Viveiros
Journal:  Development       Date:  2015-04-29       Impact factor: 6.868

Review 5.  Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression.

Authors:  Etsu Tashiro; Ayako Tsuchiya; Masaya Imoto
Journal:  Cancer Sci       Date:  2007-03-14       Impact factor: 6.716

6.  hRUL138, a novel human RNA-binding RING-H2 ubiquitin-protein ligase.

Authors:  Stefan G Kreft; Michael Nassal
Journal:  J Cell Sci       Date:  2003-02-15       Impact factor: 5.285

Review 7.  Nuclear cyclin D1: an oncogenic driver in human cancer.

Authors:  Jong Kyong Kim; J Alan Diehl
Journal:  J Cell Physiol       Date:  2009-08       Impact factor: 6.384

8.  Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in RIG-I-mediated antiviral innate immunity.

Authors:  Kanako Kuniyoshi; Osamu Takeuchi; Surya Pandey; Takashi Satoh; Hidenori Iwasaki; Shizuo Akira; Taro Kawai
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-27       Impact factor: 11.205

9.  Interaction profiling of RNA-binding ubiquitin ligases reveals a link between posttranscriptional regulation and the ubiquitin system.

Authors:  Andrea Hildebrandt; Gregorio Alanis-Lobato; Andrea Voigt; Kathi Zarnack; Miguel A Andrade-Navarro; Petra Beli; Julian König
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

10.  K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway.

Authors:  Elsa Lauwers; Christophe Jacob; Bruno André
Journal:  J Cell Biol       Date:  2009-04-27       Impact factor: 10.539

View more
  4 in total

1.  DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis.

Authors:  Yuan-Jie Liu; Jie-Pin Li; Shu-Hong Zeng; Mei Han; Shen-Lin Liu; Xi Zou
Journal:  Pharmgenomics Pers Med       Date:  2021-09-16

2.  The A to I editing landscape in melanoma and its relation to clinical outcome.

Authors:  Austeja Amweg; Marina Tusup; Phil Cheng; Ernesto Picardi; Reinhard Dummer; Mitchell P Levesque; Lars E French; Emmanuella Guenova; Severin Läuchli; Thomas Kundig; Mark Mellett; Steve Pascolo
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

Review 3.  Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis.

Authors:  Xiu Yin; Qingbin Liu; Fen Liu; Xinchen Tian; Tinghao Yan; Jie Han; Shulong Jiang
Journal:  Front Cell Dev Biol       Date:  2022-07-06

Review 4.  Role of K63-linked ubiquitination in cancer.

Authors:  Liangzi Cao; Xiaofang Liu; Bowen Zheng; Chengzhong Xing; Jingwei Liu
Journal:  Cell Death Discov       Date:  2022-10-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.